Fetal Cell Receptors Repertoire

Venous Ulcer Clinical Trial

— MoreCCR  

Official title:

"Study of CCR Receptor Overexpression in Fetal Microchimeric Cells: Proof of Concept Before a Potential Clinical Trial"

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06031714
• Other study ID #: APHP230731
• Secondary ID: 2023-A00404-41
• Status: Recruiting
• Phase: N/A
• Start date: February 6, 2024
• Est. completion date: February 1, 2027

Study information

• Verified date: April 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Sélim ARACTINGI, MD, PHD
• Phone: 00 33 1 58 41 18 13
• Email: selim.aractingi[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.

Description:

The aim of regenerative medicine is to repair damaged tissue using different sources of autologous or heterologous stem cells. These cells are then cultured to achieve amplification and differentiation adapted to the cell type of the organ to be repaired. These methods are potentially effective, but involve risks and limitations, in particular the risks of genetic modifications during culture or contamination by residual ES or iPS cells. Immunosuppressive treatment is also necessary if the source of stem cells is allogeneic. Finally, implantation of this type of culture may also be unsuccessful.

Our team is seeking for an alternative strategy to these methods. This relies on the presence of a niche of foetal cells transferred during pregnancy that persist after delivery. In fact, all mammalian pregnancies lead to foetal-maternal cell transfer. The foetal cells -transferred to the maternal circulation- contain different types of stem cells that will remain in the maternal bone marrow and persist there for the rest of the mother's life. The team has shown that in the event of cutaneous wounds in post-gestational mice, a population of CD11b+ CD34+ CD31+ foetal progenitors was recruited from the maternal bone marrow to the cutaneous granulation tissue. These cells over-express the chemokine receptor CCR2 compared with their adult counterparts. Consequently, the injection of low, so-called physiological, doses of the CCL2 chemokine subcutaneously into wounds accelerates normal wound healing and restores delayed healing in two pathological models. This pro-healing activity is linked to the specific recruitment of foetal stem cells to the site of injected wounds. These low doses of CCL2 never affected wound healing in virgin mice, confirming that this type of treatment does not alter the homeostasis of adult cells.

The therapeutic strategy the investigators are proposing, entitled "natural stem therapy", is based on this reservoir of foetal stem cells present in every woman who has had at least one pregnancy, i.e. more than 60% of adult women in western countries. In order to test the validity of this concept, it is important to ascertain the pathways by which foetal cells are chemoattracted in the human species, in particular the CCR2/CCL2 pathway.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: February 1, 2027
• Est. primary completion date: July 1, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Common criteria :

• Adult women,

• Post-partum: having been pregnant for any length of time,

• Having signed a free and informed consent form,

• Primiparous or multiparous,

• Affiliated to a health insurance

Patients :

• Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer

Control group patients :

• Volunteers,

• Age-matched,

• Without skin ulcers.

There are no specific criteria for children.

Exclusion Criteria:

• Minors (for patients)

• Under court protection, curatorship, guardianship (for patients)

• Immunocompromised patients for any reason whatsoever

• Refusal of consent

• Refusal of blood and/or saliva samples for themselves or a member of their family

Related Conditions & MeSH terms

• Diabetic Ulcer
• Ulcer
• Varicose Ulcer
• Venous Ulcer

Intervention

Other:
• Saliva sampling
HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
• Blood sampling
Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells, The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.
• Interviews
V2 and/or V3
• Clinical examination
V2 and/or V3

Locations

Country	Name	City	State
France	Dermatology unit - Cochin Hospital - APHP	Paris	Ile De France

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transcriptomic analysis by single cell sequencing	Transcriptomic analysis by single cell RNA sequencing (Smart-seq3 protocol) of fetal cells sorted from peripheral blood	Month 1 up to month 5